Menu
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants with Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3).
LY3437943 is a novel synthetic peptide which shows potent agonist activity at glucose dependent insulinotropic polypeptide, GLP-1, and glucagon receptors. LY3437943 demonstrated body weight reduction in preclinical models. Data from clinical studies suggest that LY3437943 may represent a pharmacologic treatment option that could substantially reduce weight.
This study will investigate the impact of LY3437943 on cardiovascular events. Study GZBM is designed to demonstrate that LY3437943 is not associated with excessive cardiovascular risk.
You may be eligible for the study if you meet the following criteria.
Have established CV disease with at least 1 of the following.
Please contact CDH Research Institute on 07 5408 0900 for additional information or use the email link below. You can also share details of this study to social media via the links below?
Clinical trials are important because they serve as the foundation for most medical advances.
